 |  |  |  |  |  |  |  |
PAN4ND
Screening and Drug Development
Screening and Drug Development
Screening, the process of finding new active compounds against a chosen target for a
particular disease, can be performed using various technical capacities and different
schemas against targets which are:
Screening takes place at the very beginning of the R&D process. The aim is to identify
hits that can enter a drug development programme
Standardizing screening methodologies. View process.
Working as a network, it is important that methodologies and
protocols of screening assays are harmonized between the
different partner institutions who belong to the network. This will enable to compare
results obtained in different labs and facilitate collaboration and understanding among
groups. These standardized screening methodologies will be gathered in a Research
Manual to the use of the network.
Papers
Innovative lead discovery strategies for tropical diseases. Solomon Nwaka, Alan
Hudson. Nature Reviews Drug Discovery 5, 941 - 955 (2006) Review
Antimalarial drug discovery: efficacy models for compound screening. David A.
Fidock, Philip J. Rosenthal, Simon L. Croft, Reto Brun, Solomon Nwaka. Nature Reviews
Drug Discovery 3, 509 - 520 (01 Jun 2004) Review
Opportunities and challenges in antiparasitic drug discovery. Pink, R., A. Hudson,
et al. Nature Reviews Drug Discovery 4 (9): 727-740 (2005) Review
Current scenario of drug development for leishmaniasis. Croft, S. L., K. Seifert, et
al. Indian J Med Res 123(3): 399-410.(2006)
New developments in human African trypanosomiasis. Brun, R. and O. Balmer.
Curr Opin Infect Dis 19(5): 415-20 (2006)
Animal models for infectious diseases caused by parasites: Leishmaniasis.
Oliveira, C. I. d., M. J. Teixeira, et al. Drug Discovery Today: Disease Models 1(1): 81-86
(2004)
Databases
Low Hanging Fruit database
Other related links
Screening and Drug Discovery in Wikipedia
particular disease, can be performed using various technical capacities and different
schemas against targets which are:
- sub-cellular (eg. enzymatic or chemical)
- cellular
- supra-cellular target (tissue or whole animal)
Screening takes place at the very beginning of the R&D process. The aim is to identify
hits that can enter a drug development programme
- Hit selection
- Hit expansion
- Lead optimization
- Drug Candidate selection).
Standardizing screening methodologies. View process.
Working as a network, it is important that methodologies and
protocols of screening assays are harmonized between the
different partner institutions who belong to the network. This will enable to compare
results obtained in different labs and facilitate collaboration and understanding among
groups. These standardized screening methodologies will be gathered in a Research
Manual to the use of the network.
Papers
Innovative lead discovery strategies for tropical diseases. Solomon Nwaka, Alan
Hudson. Nature Reviews Drug Discovery 5, 941 - 955 (2006) Review
Antimalarial drug discovery: efficacy models for compound screening. David A.
Fidock, Philip J. Rosenthal, Simon L. Croft, Reto Brun, Solomon Nwaka. Nature Reviews
Drug Discovery 3, 509 - 520 (01 Jun 2004) Review
Opportunities and challenges in antiparasitic drug discovery. Pink, R., A. Hudson,
et al. Nature Reviews Drug Discovery 4 (9): 727-740 (2005) Review
Current scenario of drug development for leishmaniasis. Croft, S. L., K. Seifert, et
al. Indian J Med Res 123(3): 399-410.(2006)
New developments in human African trypanosomiasis. Brun, R. and O. Balmer.
Curr Opin Infect Dis 19(5): 415-20 (2006)
Animal models for infectious diseases caused by parasites: Leishmaniasis.
Oliveira, C. I. d., M. J. Teixeira, et al. Drug Discovery Today: Disease Models 1(1): 81-86
(2004)
Databases
Low Hanging Fruit database
Other related links
Screening and Drug Discovery in Wikipedia
P
A
N
4
N
D
A
N
4
N
D
